GenSight will participate to the SOE 2019 Congress, the European Congress of Ophthalmology in Nice (France), from 13–16 June 2019.
Two presentations will focus on GS030, our lead gene therapy product candidate, an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).
GS030 – Optogenetics in Retinitis Pigmentosa (RP)
Free Paper presentation
Title: A Phase 1/2 optogenetic retinal gene therapy clinical trial for non-syndromic retinitis pigmentosa: the PIONEER study
- Oral speaker: Miss Simona Degli Esposti, Locum Research Consultant, NIHR Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust
- Session Name: Retina
- Session Date: Friday, 14 June 2019
- Session Time: 10:00-11:30
- Location: Gallieni 1+2
- Official Presentation Reference: FP06-03-RET
Free Paper presentation
Title: GS030-DP, a gene therapy product for retinitis pigmentosa, is well tolerated after bilateral intravitreal administration and exposure to 595-nm LED light in blind rd1 mice
- Oral speaker: Joël CHAVAS, Scientific Leader and Lead System Designer, GenSight Biologics
- Session Name: Retina
- Session Date: Friday, 14 June 2019
- Session Time: 10:00-11:30
- Location: Gallieni 1+2
- Official Presentation Reference: FP06-02-RET